Ranitidine: Difference between revisions
Neil.m.young (talk | contribs) (Text replacement - "==Sources==" to "==References==") |
Neil.m.young (talk | contribs) (Text replacement - "0 mg" to "0mg") |
||
| Line 5: | Line 5: | ||
==Adult Dosing== | ==Adult Dosing== | ||
GERD: | GERD: 150mg PO BID | ||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
GERD: 5- | GERD: 5-10mg/kg/day PO BID | ||
==Special Populations== | ==Special Populations== | ||
| Line 14: | Line 14: | ||
*Lactation: Probably Safe | *Lactation: Probably Safe | ||
*Renal Dosing | *Renal Dosing | ||
**Adult: CrCl < 50: | **Adult: CrCl < 50: 150mg Qday; CrCl < 10: 75 -150mg Qday; HD: give dose after dialysis | ||
**Pediatric: CrCl < 10-50: decrease dose 50%; CrCl< 10: decrease dose 75%; HD: Give dose after dialysis | **Pediatric: CrCl < 10-50: decrease dose 50%; CrCl< 10: decrease dose 75%; HD: Give dose after dialysis | ||
*Hepatic Dosing | *Hepatic Dosing | ||
Revision as of 20:33, 24 July 2016
General
- Type: H2 blocker
- Dosage Forms: 75, 150, 300
- Common Trade Names: Zantac
Adult Dosing
GERD: 150mg PO BID
Pediatric Dosing
GERD: 5-10mg/kg/day PO BID
Special Populations
- Pregnancy Rating: B
- Lactation: Probably Safe
- Renal Dosing
- Adult: CrCl < 50: 150mg Qday; CrCl < 10: 75 -150mg Qday; HD: give dose after dialysis
- Pediatric: CrCl < 10-50: decrease dose 50%; CrCl< 10: decrease dose 75%; HD: Give dose after dialysis
- Hepatic Dosing
- Adult: Not defined
- Pediatric: not defined
Contraindications
- Allergy to class/drug
- Porphyria
- Caution if impairment of liver or kidneys
- Caution in chronic pulmonary disease
- Caution if diabetes mellitus
- Caution if immunocompromised
Adverse Reactions
Serious
- Thrombocytopenia
- Hepatotoxicity
- Pneumonia
Common
- Nausea/vomiting/diarrhea
- Fatigue
- Headache
- Rash
- Myalgia
- Xerostomia
Pharmacology
- Half-life: 2-3 hr, Renal impairment: 5 hr
- Metabolism: Liver
- Excretion: Urine, Feces
- Mechanism of Action: H2 blocker